JP2008539184A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539184A5
JP2008539184A5 JP2008508156A JP2008508156A JP2008539184A5 JP 2008539184 A5 JP2008539184 A5 JP 2008539184A5 JP 2008508156 A JP2008508156 A JP 2008508156A JP 2008508156 A JP2008508156 A JP 2008508156A JP 2008539184 A5 JP2008539184 A5 JP 2008539184A5
Authority
JP
Japan
Prior art keywords
protein
immunogenic fragment
fragment
vaccine
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008508156A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539184A (ja
Filing date
Publication date
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed filed Critical
Priority claimed from PCT/EP2006/003918 external-priority patent/WO2006114312A2/en
Publication of JP2008539184A publication Critical patent/JP2008539184A/ja
Publication of JP2008539184A5 publication Critical patent/JP2008539184A5/ja
Pending legal-status Critical Current

Links

JP2008508156A 2005-04-26 2006-04-24 ワクチン Pending JP2008539184A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
PCT/EP2006/003918 WO2006114312A2 (en) 2005-04-26 2006-04-24 Vaccine

Publications (2)

Publication Number Publication Date
JP2008539184A JP2008539184A (ja) 2008-11-13
JP2008539184A5 true JP2008539184A5 (https=) 2009-04-23

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508156A Pending JP2008539184A (ja) 2005-04-26 2006-04-24 ワクチン

Country Status (12)

Country Link
US (1) US20090181052A1 (https=)
EP (1) EP1877086A2 (https=)
JP (1) JP2008539184A (https=)
KR (1) KR20080005585A (https=)
AR (1) AR054259A1 (https=)
AU (1) AU2006239422A1 (https=)
CA (1) CA2606092A1 (https=)
EA (1) EA013326B1 (https=)
MX (1) MX2007013472A (https=)
NO (1) NO20075194L (https=)
SG (1) SG159525A1 (https=)
WO (1) WO2006114312A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0916732B1 (pt) * 2008-07-31 2021-06-29 Glaxosmithkline Biologicals S.A. Vacina para a prevenção de doença ou infecção relacionada ao papilomavirus humano (hpv) compreendendo partículas semelhantes ao vírus hpv 16 e hpv 18
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
US20140127260A1 (en) 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
WO2021163002A1 (en) 2020-02-14 2021-08-19 Merck Sharp & Dohme Corp. Hpv vaccine
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
EP4387660A1 (en) 2021-08-19 2024-06-26 Merck Sharp & Dohme LLC Thermostable lipid nanoparticle and methods of use thereof
WO2024254226A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
WO2004056389A1 (en) * 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Similar Documents

Publication Publication Date Title
JP2008534467A5 (https=)
JP2006512413A5 (https=)
JP2012010713A5 (https=)
JP2015028057A (ja) ヒトパピローマウイルス感染症の治療又は予防のための複数型hpvペプチド組成物及び方法
CA2510457A1 (en) Hpv-16 and -18 l1 vlp vaccine
Toh et al. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art
US20170143818A1 (en) Intradermal hpv peptide vaccination
MX376568B (es) Vacunas mejoradas para el virus del papiloma humano y métodos para utilizarlas.
JP2008539184A5 (https=)
CN112618713A (zh) 抗hpv及抗妇科炎症复合卵黄球蛋白组合物及凝胶剂
Roden et al. The impact of preventive HPV vaccination
US20090181052A1 (en) Vaccine
Ramet et al. Position paper—HPV and the primary prevention of cancer; improving vaccine uptake by paediatricians
JP2013540421A5 (https=)
US7858098B2 (en) Vaccine
RU2006143804A (ru) Вакцина против вирусов папилломы человека hpv16 и hpv18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31,45 или 52
JP2008539182A5 (https=)
CN101116745B (zh) 人乳头瘤病毒的病毒样颗粒疫苗
Hariharan et al. Genotypes of the human papillomavirus: Relevance to Indian field trials of the vaccine
EA200702077A1 (ru) Вакцина
Bubeník Human papillomavirus (HPV) and HPV-associated tumour vaccines
Sitarz HPV vaccines
Yin Development of vaccine against human papillomavirus types 3, 10 and 77
Guo et al. Development Status and trend of HPV vaccine
Uslimgazieva et al. HUMAN PAPILLOMA VIRUS AND HUMAN PAPILLOMA VIRUS VACCINES